Anti-Her2 Car-T Cells
HER2-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.Cell therapyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the HER2-positive Advanced Malignant Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide UTC Therapeutics Inc. | N/A | D |
Fludarabine UTC Therapeutics Inc. | N/A | D |
Same molecule, other indications
Anti-Her2 Car-T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →